Michael Tomblyn

663 total citations
20 papers, 399 citations indexed

About

Michael Tomblyn is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Tomblyn has authored 20 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Pathology and Forensic Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Tomblyn's work include Radiopharmaceutical Chemistry and Applications (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Michael Tomblyn is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Michael Tomblyn collaborates with scholars based in United States, United Kingdom and Sweden. Michael Tomblyn's co-authors include Michael J. Katin, Paul E. Wallner, Richard A. Popple, Daniel J. Indelicato, Lei Dong, K Langen, Edward J. Kasarskis, Kenneth Forster, William T. C. Yuh and Nina A. Mayr and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

Michael Tomblyn

20 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Tomblyn United States 9 202 140 103 97 57 20 399
Daniel Yakar United States 12 128 0.6× 183 1.3× 56 0.5× 62 0.6× 45 0.8× 20 462
Michael G. McKenna United States 9 277 1.4× 276 2.0× 70 0.7× 213 2.2× 53 0.9× 17 508
Bernhard Vanselow Germany 10 92 0.5× 98 0.7× 73 0.7× 29 0.3× 76 1.3× 13 413
Simonetta Saldi Italy 12 105 0.5× 119 0.8× 67 0.7× 104 1.1× 49 0.9× 35 290
A. Paix France 7 61 0.3× 83 0.6× 115 1.1× 48 0.5× 35 0.6× 12 257
Jean-François Rosier Belgium 11 60 0.3× 154 1.1× 149 1.4× 53 0.5× 65 1.1× 14 389
Katrina Andrews United Kingdom 6 161 0.8× 119 0.8× 71 0.7× 55 0.6× 79 1.4× 10 365
J. Glees United Kingdom 7 86 0.4× 116 0.8× 147 1.4× 27 0.3× 61 1.1× 11 393
V. Kouloulias Greece 10 50 0.2× 56 0.4× 45 0.4× 30 0.3× 65 1.1× 30 291
Monika Dadrich Germany 6 214 1.1× 177 1.3× 75 0.7× 14 0.1× 36 0.6× 6 426

Countries citing papers authored by Michael Tomblyn

Since Specialization
Citations

This map shows the geographic impact of Michael Tomblyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tomblyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tomblyn more than expected).

Fields of papers citing papers by Michael Tomblyn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tomblyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tomblyn. The network helps show where Michael Tomblyn may publish in the future.

Co-authorship network of co-authors of Michael Tomblyn

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tomblyn. A scholar is included among the top collaborators of Michael Tomblyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tomblyn. Michael Tomblyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hurwitz, Mark, John Buscombe, Heather A. Jacene, et al.. (2020). ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. American Journal of Clinical Oncology. 43(8). 539–544. 2 indexed citations
2.
Seider, Michael J., Stephanie L. Pugh, Corey J. Langer, et al.. (2018). Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Annals of Nuclear Medicine. 32(8). 553–560. 11 indexed citations
3.
Abuodeh, Y.A., Kamran A. Ahmed, Michelle Echevarria, et al.. (2017). Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Therapeutic Advances in Hematology. 8(4). 129–138. 2 indexed citations
4.
Witzig, Thomas E., Michael Tomblyn, Jamal Misleh, et al.. (2014). Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 99(11). 1738–1745. 19 indexed citations
5.
Nilsson, Sten, Michael Tomblyn, Paul Cislo, Jonathan Reuning‐Scherer, & Chris Parker. (2014). Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study.. Journal of Clinical Oncology. 32(15_suppl). 5069–5069. 8 indexed citations
6.
Santos, Jennifer De Los, Richard A. Popple, Nzhde Agazaryan, et al.. (2013). Image Guided Radiation Therapy (IGRT) Technologies for Radiation Therapy Localization and Delivery. International Journal of Radiation Oncology*Biology*Physics. 87(1). 33–45. 111 indexed citations
7.
Tomblyn, Michael, Michael J. Katin, & Paul E. Wallner. (2013). The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymore. Cancer Control. 20(1). 60–71. 29 indexed citations
8.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2013). Anti-CD22 radioimmunotherapy (RIT) combined with anti-CD20 immunotherapy in aggressive non-Hodgkin lymphoma (NHL): Phase I results. 54. 1368–1368. 1 indexed citations
9.
10.
Tomblyn, Michael, Bryan Goldman, Charles R. Thomas, et al.. (2012). Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414). Journal of Thoracic Oncology. 7(5). 906–912. 38 indexed citations
11.
Tomblyn, Michael. (2012). The Role of Bone-Seeking Radionuclides in the Palliative Treatment of Patients with Painful Osteoblastic Skeletal Metastases. Cancer Control. 19(2). 137–144. 42 indexed citations
12.
Tomblyn, Michael, Thomas E. Witzig, Andrew L. Himelstein, et al.. (2012). Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results. Blood. 120(21). 3680–3680. 1 indexed citations
13.
Tomblyn, Michael. (2012). Radioimmunotherapy for B-Cell Non-Hodgkin Lymphomas. Cancer Control. 19(3). 196–203. 40 indexed citations
14.
Tomblyn, Michael, Rebecca Elstrom, Andrew L. Himelstein, et al.. (2012). Novel combination of anti-CD22 radioimmunotherapy and anti-CD20 immunotherapy targeting two different antigens in non-Hodgkin lymphoma (NHL): Initial clinical experience. 53. 500–500. 2 indexed citations
15.
Seider, Michael J., Corey J. Langer, Gwen Wyatt, et al.. (2012). Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: Report of RTOG 0517.. Journal of Clinical Oncology. 30(15_suppl). TPS9150–TPS9150. 1 indexed citations
16.
Tomblyn, Michael. (2011). Addition of low-dose, involved-field external beam radiotherapy just prior to radioimmunotherapy for CD20+ lymphoma: “Priming” cell death pathways?. Journal of Clinical Oncology. 29(15_suppl). e18533–e18533. 1 indexed citations
17.
Tomblyn, Michael, Kathryn E. Dusenbery, & Marcie Tomblyn. (2009). Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review. 3(1). 58–64. 1 indexed citations
18.
Tomblyn, Michael, Mukta Arora, K. Scott Baker, et al.. (2009). Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. Journal of Clinical Oncology. 27(22). 3634–3641. 61 indexed citations
19.
Sheng, Hui, B Gerbi, Ali S. Meigooni, et al.. (2006). WE‐C‐224C‐07: Cervical Cancer Treatment: 3D Dose Determination Based On Low Energy and High Energy CT Image. Medical Physics. 33(6Part19). 2237–2237. 1 indexed citations
20.
Tomblyn, Michael, Edward J. Kasarskis, Yong Xu, & Daret K. St. Clair. (1998). Distribution of MnSOD polymorphisms in sporadic ALS patients. Journal of Molecular Neuroscience. 10(1). 65–66. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Yakar Breakdown of academic impact, for papers by Michael G. McKenna Breakdown of academic impact, for papers by Bernhard Vanselow Breakdown of academic impact, for papers by Simonetta Saldi Breakdown of academic impact, for papers by A. Paix Breakdown of academic impact, for papers by Jean-François Rosier Breakdown of academic impact, for papers by Katrina Andrews Breakdown of academic impact, for papers by J. Glees Breakdown of academic impact, for papers by V. Kouloulias Breakdown of academic impact, for papers by Monika Dadrich
Rankless by CCL
2026